Last reviewed · How we verify
DEUREMIDEVIR HYDROBROMIDE
At a glance
| Generic name | DEUREMIDEVIR HYDROBROMIDE |
|---|---|
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Clinical Trial on the Efficacy and Safety of Deuremidevir Hydrobromide Dry Suspension for the Treatment of RSV Infection in Infants and Young Children (PHASE3)
- A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension (PHASE1)
- A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (PHASE2)
- A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension (PHASE1)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension (PHASE1)
- A Study in Elderly Chinese Subjects With Underlying Diseases (PHASE1)
- A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function (PHASE1)
- A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DEUREMIDEVIR HYDROBROMIDE CI brief — competitive landscape report
- DEUREMIDEVIR HYDROBROMIDE updates RSS · CI watch RSS